Skip to main content

BioFocus DPI, GSK, Alnylam, Shanghai GenePharma

BioFocus DPI Obtains Global License to Cresset Software
BioFocus DPI has upgraded its software license with Cresset BioMolecular Discovery, gaining global access to the entire range of Cresset’s molecular field software for use in drug discovery.
The new license also extends BioFocus DPI’s coverage to include its parent company, Galapagos. BioFocus DPI and Galapagos will now be able to apply molecular field technology to projects including internal research, compound library design, or drug-discovery projects for clients.
BioFocus DPI and Cresset have been collaborating for two years on the design and synthesis of BioFocus DPI’s FieldFocus libraries for ion-channel drug discovery. 

GSK Purchases SRU BIND Reader System for UK Facility
SRU Biosystems announced this week that GlaxoSmithKline has purchased a BIND Reader system for its drug-discovery site in Harlow, UK.
SRU has developed the BIND product line for cell-based applications, small molecule/fragment screening, and antibody screening. The BIND system includes the BIND Reader, software tools, and 96-, 384-, or 1,536-well microplates with proprietary coatings for attaching cells or proteins.
The BIND Reader uses SRU Biosystems’ optical biosensor technology and can be integrated into a semi-automated or fully automated environment for kinetic or endpoint assays in an HTS mode.

Alnylam Licenses RNAi IP to China’s Shanghai GenePharma
Alnylam Pharmaceuticals this week said it has granted a non-exclusive, worldwide license to its Kreutzer-Limmer patent family to Chinese reagent shop Shanghai GenePharma for manufacturing and marketing RNAi research products and services.
The patents, according to Alnylam, cover fundamental aspects of the structure and uses of RNAi products, including their use to mediate RNAi in mammalian cells and of RNAi-related mechanisms.
"Providing this license to Shanghai GenePharma represents our first business transaction in China,” Jason Rhodes, vice president of business development at Alnylam, said in a statement.
Specific terms of the license were not disclosed.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.